The challenges in providing safe, effective, affordable cannabis-based medicines for unapproved indications

Wayne D Hall and Michael Farrell
Med J Aust 2018; 209 (5): . || doi: 10.5694/mja18.00445
Published online: 3 September 2018

A cautious response to public interest in medical uses of cannabis products remains appropriate

Over the past 20 years or more, governments in many countries have struggled with how best to respond to the requests of patients, families and some doctors that they be allowed to use unapproved cannabis-based medicines to treat serious medical conditions that have failed to respond to conventional treatment.1 In Australia, parents of children with cancer or intractable forms of epilepsy have recently persuaded state and federal governments to permit access to cannabis-based products for medical use under the Special Access Scheme of the Therapeutic Goods Act.2

  • 1 Centre for Youth Substance Abuse Research, University of Queensland, Brisbane, QLD
  • 2 National Addiction Centre, King's College London, London, United Kingdom
  • 3 National Drug and Alcohol Research Centre, UNSW, Sydney, NSW


Competing interests:

We have each advised the Therapeutic Goods Administration on the evidence of the safety and effectiveness of cannabinoids in the treatment of various illnesses. Wayne Hall is a member of the Australian Advisory Council on the Medicinal Uses of Cannabis.

  • 1. Joy JE, Watson SJ, Benson JA, editors. Marijuana and medicine: assessing the science base. Washington (DC): The National Academies Press, 1999.
  • 2. Therapeutic Goods Administration. Guidance for the use of medicinal cannabis in Australia: overview. Version 1, December 2017. Canberra: Commonwealth of Australia, 2017. (viewed Jan 2018).
  • 3. Chen K-A, Farrar M, Cardamone M, et al. Cannabidiol for treating drug-resistant epilepsy in children: the New South Wales experience. Med J Aust 2018; 209: 217-221.
  • 4. Freeman JL. Safety of cannabidiol prescribed for children with refractory epilepsy. Med J Aust 2018; 209: 228-229.
  • 5. Stockings E, Zagic D, Campbell G, et al. Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence. J Neurol Neurosurg Psychiatry 2018; 89: 741-753.
  • 6. US Food and Drug Administration. FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy [media release]. 25 June 2018. (viewed June 2018).
  • 7. Lintzeris N, Driels J, Elias N, et al. Medicinal cannabis in Australia, 2016: the Cannabis as Medicine Survey (CAMS-16). Med J Aust 2018; 209: 211-216.
  • 8. Lucas P. It can’t hurt to ask; a patient-centered quality of service assessment of Health Canada’s medical cannabis policy and program. Harm Reduct J 2012; 9: 2.
  • 9. O’Connell TJ, Bou-Matar CB. Long term marijuana users seeking medical cannabis in California (2001–2007): demographics, social characteristics, patterns of cannabis and other drug use of 4117 applicants. Harm Reduct J 2007; 4: 16.
  • 10. National Academies of Sciences, Engineering, and Medicine. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. Washington (DC): The National Academies Press, 2017. (viewed June 2018).
  • 11. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA 2015; 313: 2456-2473.
  • 12. Stockings E, Campbell G, Hall W, et al. Cannabis and cannabinoids for the treatment of people with chronic non-cancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. Pain 2018; doi: 10.1097/j.pain.0000000000001293 [Epub ahead of print].


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.